Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients

被引：10

作者：

Luo, Mengqi ^{[1
]}

Zhou, Bin ^{[1
]}

Hou, Jinlin ^{[1
]}

Jiang, Deke ^{[1
]}

机构：

[1] Southern Med Univ, Dept Infect Dis & Hepatol Unit, State Key Lab Organ Failure Res,Nanfang Hosp, Guangdong Key Lab Viral Hepatitis Res,Inst Liver, Guangzhou 510515, Peoples R China

来源：

HEPATOLOGY RESEARCH | 2022年 / 52卷 / 04期

基金：

中国国家自然科学基金;

关键词：

chronic; Hepatitis B; predict; withdrawal; CORE-RELATED ANTIGEN; SERUM HBV RNA; HBEAG-NEGATIVE PATIENTS; LONG-TERM TREATMENT; PROTEIN; 10; SERUM; SURFACE-ANTIGEN; ENTECAVIR THERAPY; CLINICAL-OUTCOMES; OFF-TREATMENT; LAMIVUDINE TREATMENT;

D O I：

10.1111/hepr.13749

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Aim To summarize HBV-related biomarkers predicting nucleos(t)ide analogs (NAs) discontinuation and hepatitis B virus (HBV) recurrence after drug withdrawal in chronic hepatitis B (CHB) patients, providing references for clinical medication, so as to manage CHB patients more scientifically. Methods Related pieces of literature were retrieved in PubMed and the results were sorted out. We then analyzed and summarized these articles. Results We found that HBV related biomarkers maybe could predict NAs withdrawal safely and the possibility of relapse after treatment cessation, including hepatitis B e antigen (HBeAg), hepatitis B surface antigen (HBsAg), HBV DNA, HBV RNA, pregenomic-RNA (pgRNA), hepatitis B core-related antigen (HBcrAg), hepatitis B core antibody (anti-HBc), and models containing several indicators for predicting the effectiveness of treatment. Conclusions HBV DNA, HBV RNA, pgRNA, HBcrAg, anti-HBc, as well as the prediction models formed by several biomarkers could predict the safe discontinuation of NAs before HBsAg loss and recurrence.

引用

页码：337 / 351

页数：15

共 98 条

[1] The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy [J].

Berg, Thomas ;

Lampertico, Pietro .

JOURNAL OF HEPATOLOGY, 2021, 75 (02) :474-480

[2] Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study [J].

Berg, Thomas ;

Simon, Karl-Georg ;

Mauss, Stefan ;

Schott, Eckart ;

Heyne, Renate ;

Klass, Dietmar M. ;

Eisenbach, Christoph ;

Welzel, Tania Mara ;

Zachoval, Reinhart ;

Felten, Gisela ;

Schulze-zur-Wiesch, Julian ;

Cornberg, Markus ;

Op den Brouw, Marjoleine L. ;

Jump, Belinda ;

Reiser, Hans ;

Gallo, Lothar ;

Warger, Tobias ;

Petersen, Joerg .

JOURNAL OF HEPATOLOGY, 2017, 67 (05) :918-924

[3] Natural Killer Cell Phenotype Modulation and Natural Killer/T-Cell Interplay in Nucleos(t)ide Analogue-Treated Hepatitis e Antigen-Negative Patients With Chronic Hepatitis B [J].

Boni, Carolina ;

Lampertico, Pietro ;

Talamona, Lavinia ;

Giuberti, Tiziana ;

Invernizzi, Federica ;

Barili, Valeria ;

Fisicaro, Paola ;

Rossi, Marzia ;

Cavallo, Maria Cristina ;

Vecchi, Andrea ;

Pedrazzi, Giuseppe ;

Alfieri, Arianna ;

Colombo, Massimo ;

Missale, Gabriele ;

Ferrari, Carlo .

HEPATOLOGY, 2015, 62 (06) :1697-1709

[4] Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study [J].

Cao, Jiawei ;

Chi, Heng ;

Yu, Tao ;

Li, Zhandong ;

Hansen, Bettina E. ;

Zhang, Xiaoyong ;

Zhong, Chunxiu ;

Sun, Jian ;

Hou, Jinlin ;

Janssen, Harry L. A. ;

Peng, Jie .

JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (04) :581-589

[5] Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy [J].

Carey, Ivana ;

Gersch, Jeffrey ;

Wang, Bo ;

Moigboi, Christiana ;

Kuhns, Mary ;

Cloherty, Gavin ;

Dusheiko, Geoffrey ;

Agarwal, Kosh .

HEPATOLOGY, 2020, 72 (01) :42-57

[6] Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients [J].

Chan, Henry L-Y ;

Wong, Grace L-H ;

Chim, Angel M-L ;

Chan, Hoi-Yun ;

Chu, Shirley H-T ;

Wong, Vincent W-S .

ANTIVIRAL THERAPY, 2011, 16 (08) :1249-1257

[7] The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients [J].

Chen, C-H ;

Hsu, Y-C ;

Lu, S-N ;

Hung, C-H ;

Wang, J-H ;

Lee, C-M ;

Hu, T-H .

JOURNAL OF VIRAL HEPATITIS, 2018, 25 (05) :590-597

[8] Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection [J].

Chen, Chien-Hung ;

Hung, Chao-Hung ;

Hu, Tsung-Hui ;

Wang, Jing-Houng ;

Lu, Sheng-Nan ;

Su, Pei-Fang ;

Lee, Chuan-Mo .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (11) :1984-+

[9] The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment [J].

Chen, Chien-Hung ;

Lu, Sheng-Nan ;

Hung, Chao-Hung ;

Wang, Jing-Houng ;

Hu, Tsung-Hui ;

Changchien, Chi-Sin ;

Lee, Chuan-Mo .

JOURNAL OF HEPATOLOGY, 2014, 61 (03) :515-522

[10] Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis [J].

Chen, Y. C. ;

Peng, C. Y. ;

Jeng, W. J. ;

Chien, R. N. ;

Liaw, Y. F. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (10) :1182-1191

← 1 2 3 4 5 6 7 8 9 10 →